PF-Atlas › Clinical Trials › NCT03691779

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

ELX/TEZ/IVA · Phase 3

Registry ID
NCT03691779
Phase
Phase 3
Status
Completed
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-10-02
Enrollment
71
Locations
21

About this trial

This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.

View NCT03691779 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761ELX/TEZ/IVA — NCT04105972
Medical disclaimer. This page summarizes public trial data for NCT03691779 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.